Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis CArase Y. · Ikeda K. · Suzuki F. · Suzuki Y. · Saitoh S. · Kobayashi M. · Akuta N. · Someya T. · Koyama R. · Hosaka T. · Sezaki H. · Kobayashi M. · Kumada H.
Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Toranomon, Tokyo, Japan
Objective: The purpose of this study was to elucidate the long-term outcome after interferon (IFN) therapy in chronic hepatitis C elderly patients. Methods: We studied the incidence of hepatocellular carcinoma (HCC) and survival probability after the initiation of IFN therapy in 500 Japanese chronic hepatitis C patients >60 years. The mean age of initiation of IFN was 63 years and the mean follow-up period was 7.4 years. Cox proportional hazard regression analysis was used to evaluate the long-term outcome after initiation of IFN therapy.Sustained virological response (SVR) was defined as negative HCV-RNA by RT-nested PCR 6 months after the completion of long-term IFN therapy. Non-response (NR) was applied to patients who did not show SVR. Hepatic fibrosis was defined as the fibrosis score (score 0–4) according to Knodell et al. Results: 140 patients (28%) had an SVR and 360 patients (72%) had an NR. 71 of 500 patients developed HCC during follow-up. The cumulative incidence of HCC was 9.6% at the 5th year, 17.4% at the 10th year, and 31.3% at the 15th year. HCC developed with significance when: (1) HCV was not cleared after IFN therapy (p < 0.0001), (2) sex was male (p < 0.0001), and (3) staging of liver fibrosis was >2 (p = 0.008). 53 of the patients died. The cumulative survival probability was 95.7% at the 5th year, 86.4% at the 10th year, and 78% at the 15th year. Patients achieved a long survival with significance when: (1) staging of liver fibrosis was 1 (p < 0.0001), (2) HCV was cleared after IFN therapy (p = 0.034), and (3) sex was female (p = 0.015). Conclusion: Chronic hepatitis C patients with clearance of HCV after IFN therapy had a significantly reduced risk of HCC appearance and achieved prolonged survival even if they are ≧60 years.
Yasuji Arase, MD
Department of Gastroenterology, Toranomon Hospital
2-2-2 Toranomon, Minato-ku, Tokyo 105-8470 (Japan)
Tel. +81 3 3588 1111, Fax +81 3 3582 7068
Received: December 14, 2005
Accepted: December 21, 2005
Number of Print Pages : 8
Number of Figures : 2, Number of Tables : 6, Number of References : 18
Intervirology (International Journal of Basic and Medical Virology)
Vol. 50, No. 1, Year 2007 (Cover Date: December 2006)
Journal Editor: Liebert, U.G. (Leipzig)
ISSN: 0300–5526 (print), 1423–0100 (Online)
For additional information: http://www.karger.com/INT